Gastroparesis: From concepts to management

Nutrition in Clinical Practice

Volumn 28, Issue 4, 2013, Pages 437-447

  Bouras, Ernest P ^a   Vazquez Roque, Maria I ^a   Aranda Michel, Jaime ^a  

^a MAYO CLINIC   (United States)

Author keywords

enteral nutrition; gastric emptying; gastrointestinal motility; gastroparesis; nutritional support

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; AMYLIN DERIVATIVE; ANTIEMETIC AGENT; AZITHROMYCIN; BOTULINUM TOXIN; CAMICINAL; CANNABINOID; CELLULOSE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; GLUCAGON LIKE PEPTIDE 1; GRANISETRON; METOCLOPRAMIDE; MIRTAZAPINE; NARCOTIC AGENT; PAPAIN; PROKINETIC AGENT; RM 131; SCOPOLAMINE; TECHNETIUM 99M; TEGASEROD; UNCLASSIFIED DRUG; VELUSETRAG;

ACUPUNCTURE; ASPIRATION; BAROSTAT; BEDTIME DOSAGE; BEZOAR; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; DIET THERAPY; DIGESTIVE SYSTEM PERFORATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; DYSTONIC DISORDER; ELECTROLYTE DISTURBANCE; ELECTROSTIMULATION; GALACTORRHEA; GASTRECTOMY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROJEJUNOSTOMY; GLYCEMIC CONTROL; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYDRATION; HYPERPROLACTINEMIA; IDIOPATHIC DISEASE; MENSTRUAL IRREGULARITY; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; OPEN STUDY; PARENTERAL NUTRITION; PROTEIN CALORIE MALNUTRITION; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; ROUX Y ANASTOMOSIS; SENSORIMOTOR FUNCTION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; STOMACH EMPTYING; STOMACH FUNCTION DISORDER; STOMACH PARESIS; TARDIVE DYSKINESIA; THYROID DISEASE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84881347348     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533613491982     Document Type: Review

References (89)

1. DeVault KR, Bouras EP, Talley NJ Practical Gastroenterology and Hepatology. Talley NJ, ed. Oxford, UK Wiley-Blackwell: ; 2010. 9-15 :
2. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013 ; 108 (1). 18-37
3. O'Brien MD, Bruce BK, Camilleri M. The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology. 1995 ; 108 (4). 1024-1029
4. Hyett B, Martinez FJ, Gill BM, et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology. 2009 ; 137 (2). 445-452
5. Horowitz M, Harding PE, Maddox A, et al. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J Gastroenterol Hepatol. 1986 ; 1: 97-113
6. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol. 1987 ; 82 (1). 29-35
7. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989 ; 32 (3). 151-159
8. Wegener M, Borsch G, Schaffstein J, Luerweg C, Leverkus F. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis. 1990 ; 8 (1). 23-36
9. Mearin F, Malagelada JR. Gastroparesis and dyspepsia in patients with diabetes mellitus. Eur J Gastroenterol Hepatol. 1995 ; 7 (8). 717-723
10. Choung RS, Locke GR, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012 ; 107 (1). 82-88
11. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993 ; 43 (4). 817-824
12. Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983 ; 98 (3). 378-384
13. He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology. 2001 ; 121 (2). 427-434
14. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986 ; 90 (6). 1919-1925
15. Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology. 2011 ; 140 (1). 101-115
16. Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol. 2011 ; 9 (12). 1056-1064
17. Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis - clinical characteristics and long-term outcomes. Am J Gastroenterol. 1997 ; 92 (9). 1501-1504
18. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998 ; 43 (11). 2398-2404
19. Vassallo M, Camilleri M, Caron BL, Low PA. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology. 1991 ; 100 (1). 252-258
20. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008 ; 103 (3). 753-763
21. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008 ; 27 (2). 186-196
22. Ghoos YF, Maes BD, Geypens BJ, et al. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology. 1993 ; 104 (6). 1640-1647
23. Szarka LA, Camilleri M, Vella A, et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol. 2008 ; 6 (6). 635-643 e1
24. Camilleri M, Hasler WL, Parkman HP, Quigley EM, Soffer E. Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology. 1998 ; 115 (3). 747-762
25. Camilleri M. Study of human gastroduodenojejunal motility: applied physiology in clinical practice. Dig Dis Sci. 1993 ; 38 (5). 785-794
26. Camilleri M, Bharucha AE, di Lorenzo C, et al. American Neurogastro-enterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil. 2008 ; 20 (12). 1269-1282
27. De Schepper HU, Cremonini F, Chitkara D, Camilleri M. Assessment of gastric accommodation: overview and evaluation of current methods. Neurogastroenterol Motil. 2004 ; 16 (3). 275-285
28. Bouras EP, Delgado-Aros S, Camilleri M, et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication: single photon emission computed tomography. Gut. 2002 ; 51 (6). 781-786
29. Chial HJ, Camilleri C, Delgado-Aros S, et al. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil. 2002 ; 14 (3). 249-253
30. Kim DY, Myung SJ, Camilleri M. Novel testing of human gastric motor and sensory functions: rationale, methods, and potential applications in clinical practice. Am J Gastroenterol. 2000 ; 95 (12). 3365-3373
31. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005 ; 62 (2). 173-181
32. Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil. 2002 ; 14 (2). 123-131
33. Tack J, Talley NJ. Functional dyspepsia - symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol. 2013 ; 10 (3). 134-141
34. Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci. 1998 ; 43 (9). 2028-2033
35. Stanghellini V, Tosetti C, Paternico A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology. 1996 ; 110 (4). 1036-1042
36. Parkman HP, Yates KP, Hasler WL, et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology. 2011 ; 141 (2). 486-498
37. Bouras EP, Scolapio JS. Gastric motility disorders: management that optimizes nutritional status. J Clin Gastroenterol. 2004 ; 38 (7). 549-557
38. Camilleri M. Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility. Am J Gastroenterol. 1994 ; 89 (10). 1769-1774
39. Ogorek CP, Davidson L, Fisher RS, Krevsky B. Idiopathic gastroparesis is associated with a multiplicity of severe dietary deficiencies. Am J Gastroenterol. 1991 ; 86 (4). 423-448
40. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010 ; 31 (1). 11-19
41. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care. 1993 ; 16 (11). 1511-1514
42. Longstreth GF, Malagelada JR, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med. 1977 ; 86 (2). 195-196
43. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983 ; 6 (5). 463-467
44. Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med. 1982 ; 96 (4). 444-446
45. Parkman HP, Mishra A, Jacobs M, et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012 ; 46 (6). 494-503
46. Parkman HP, Jacobs MR, Mishra A, et al. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci. 2011 ; 56 (1). 115-124
47. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med. 1990 ; 322 (15). 1028-1031
48. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993 ; 88 (2). 203-207
49. Vazquez Roque M, Camilleri M. Velusetrag. Drugs Future. 2011 ; 36: 447-454 :
50. Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil. 2009 ; 21 (6). 657-664
51. Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013 ; 36 (1). 41-48
52. Walstab J, Kruger D, Stark T, et al. Ginger and its pungent constituents non-competitively inhibit activation of human recombinant and native 5-HT receptors of enteric neurons. Neurogastroenterol Motil. 2013 ; 25 (5). 439 - e302
53. Kaptchuk TJ. Acupuncture: theory, efficacy, and practice. Ann Intern Med. 2002 ; 136 (5). 374-383
54. Wang L. Clinical observation on acupuncture treatment in 35 cases of diabetic gastroparesis. J Tradit Chin Med. 2004 ; 24 (3). 163-165
55. Wang CP, Kao CH, Chen WK, Lo WY, Hsieh CL. A single-blinded, randomized pilot study evaluating effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis. J Altern Complement Med. 2008 ; 14 (7). 833-839
56. Lee EJ, Frazier SK. The efficacy of acupressure for symptom management: a systematic review. J Pain Symptom Manage. 2011 ; 42 (4). 589-603
57. Rashed H, Cutts T, Abell T, et al. Predictors of response to a behavioral treatment in patients with chronic gastric motility disorders. Dig Dis Sci. 2002 ; 47 (5). 1020-1026
58. Bouras EP, Talley NJ, Camilleri M, et al. Effects of amitriptyline on gastric sensorimotor function and postprandial symptoms in healthy individuals: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2008 ; 103 (8). 2043-2050
59. Prakash C, Lustman PJ, Freedland KE, Clouse RE. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci. 1998 ; 43 (9). 1951-1956
60. Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2007 ; 52 (2). 418-424
61. Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics. 2006 ; 47 (5). 440-442
62. Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010 ; 55 (3). 675-683
63. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012 ; 366 (20). 1881-1890
64. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol. 1996 ; 91 (10). 2174-2178
65. Kao I, Drachman DB, Price DL. Botulinum toxin: mechanism of presynaptic blockade. Science. 1976 ; 193 (4259). 1256-1258
66. Bhutani MS. Gastrointestinal uses of botulinum toxin. Am J Gastroenterol. 1997 ; 92 (6). 929-933
67. Miller LS, Szych GA, Kantor SB, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol. 2002 ; 97 (7). 1653-1660
68. Lacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol. 2002 ; 97 (6). 1548-1552
69. Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005 ; 61 (7). 833-839
70. Coleski R, Anderson MA, Hasler WL. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci. 2009 ; 54 (12). 2634-2642
71. Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007 ; 26 (9). 1251-1258
72. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008 ; 103 (2). 416-423
73. Bai Y, Xu MJ, Yang X, et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion. 2010 ; 81 (1). 27-34
74. Lin Z, Forster J, Sarosiek I, McCallum RW. Treatment of gastroparesis with electrical stimulation. Dig Dis Sci. 2003 ; 48 (5). 837-848
75. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003 ; 125 (2). 421-428
76. Abell TL, Van Cutsem E, Abrahamsson H, et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion. 2002 ; 66 (4). 204-212
77. Federal Registry. 2000 ; 65: 78495-78496
78. Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J Parenter Enteral Nutr. 2003 ; 27 (4). 277-281
79. O'Grady G, Egbuji JU, Du P, Cheng LK, Pullan AJ, Windsor JA. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg. 2009 ; 33 (8). 1693-1701
80. Chu H, Lin Z, Zhong L, McCallum RW, Hou X. Treatment of high-frequency gastric electrical stimulation for gastroparesis. J Gastroenterol Hepatol. 2012 ; 27 (6). 1017-1026
81. Abell TL, Johnson WD, Kedar A, et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc. 2011 ; 74 (3). 496-503
82. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc. 1998 ; 47 (1). 67-70
83. Murr MM, Sarr MG, Camilleri M. The surgeon's role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol. 1995 ; 90 (12). 2147-2151
84. Hibbard ML, Dunst CM, Swanstrom LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J Gastrointest Surg. 2011 ; 15 (9). 1513-1519
85. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003 ; 98 (10). 2122-2129
86. Mathias JR, Fernandez A, Sninsky CA, Clench MH, Davis RH. Nausea, vomiting, and abdominal pain after Roux-en-Y anastomosis: motility of the jejunal limb. Gastroenterology. 1985 ; 88 (1 pt 1). 101-107
87. Miedema BW, Kelly KA, Camilleri M, et al. Human gastric and jejunal transit and motility after Roux gastrojejunostomy. Gastroenterology. 1992 ; 103 (4). 1133-1143
88. van der Mijle HC, Beekhuis H, Bleichrodt RP, Kleibeuker JH. Transit disorders of the gastric remnant and Roux limb after Roux-en-Y gastrojejunostomy: relation to symptomatology and vagotomy. Br J Surg. 1993 ; 80 (1). 60-64
89. Tjeerdsma HC, Smout AJ, Akkermans LM. Voluntary suppression of defecation delays gastric emptying. Dig Dis Sci. 1993 ; 38 (5). 832-836